Volcano Corporation has announced the commencement of limited market release of its US Food and Drug Administration (FDA) cleared and CE marked technology SyncVision, with cases being performed in the USA and Europe. SyncVision is currently installed in multiple limited market release sites throughout USA and Europe. According to Volcano, the new system allows co-registration of angiography with intravascular ultrasound imaging.
A study has found that bivalirudin use during percutaneous coronary intervention (PCI) is associated with less composite bleeding when compared with unfractionated heparin monotherapy, in patients with non-ST segment-elevation acute coronary syndromes or stable ischaemic heart disease.
A study among patients with diabetes, drawn from seven randomised trials, has shown that bleeding within 30 days of percutaneous coronary intervention is associated with an increased risk of one-year mortality, non-fatal myocardial infarction or stent thrombosis.
The National Institute for Health and Care Excellence (NICE) is recommending that the threshold for starting statins for the preventive treatment of cardiovascular disease (CVD) is halved from a 20% risk of developing CVD over 10 years to a 10% risk. This draft guidance – an update on its 2008 lipid modification guidance – follows new evidence for CVD risk assessment tools and the availability of generic statins.
In this new regular series ‘ECGs for the fainthearted’ Dr Heather Wetherell will be interpreting ECGs in a non-threatening and simple way. Confident interpretation of ECGs is fast becoming a dying art form. What’s more, it’s an art form that any good scientist can enjoy! ECGs are open to interpretation. The fun lies in solving the puzzle.
Data from the PLATINUM Workhorse clinical trial, presented by Dean Kereiakes, The Christ Hospital Heart and Vascular Center, Cincinnati, Ohio, USA, demonstrate low event rates out to four years with Platinum chromium everolimus-eluting stent system confirming excellent long-term performance. At four years, the Platinum chromium everolimus-eluting stent system also continued to demonstrate advantages over the Cobalt chromium everolimus-eluting stent system.
Neovasc reported that final data from its COSIRA trial assessing the efficacy and safety of the Neovasc Reducer, a novel percutaneous device for the treatment of refractory angina, were presented on March 29, 2014 in a Featured Clinical Research Presentation at ACC.14, the American College of Cardiology 63rd Annual Scientific Session & Expo.
The American College of Cardiology (ACC) has elected Patrick O’Gara, as president for the year ahead at its 63rd Annual Scientific Session.
Sorin Group announced Perceval, its sutureless aortic valve has received CE mark approval for adult age indication allowing treatment of a wider spectrum of patients with aortic stenosis and/or steno-insufficiency. Until now, only patients over 65 years of age could benefit from the Perceval technology.
ACIST Medical Systems announced at the American College of Cardiology’s 63rd Annual Scientific Session in Washington, DC the global introduction of the new ACIST RXi rapid exchange fractional flow reserve system - the world’s first rapid exchange fractional flow reserve system. This device features new technology designed to provide physicians with a fast and easy way to perform fractional flow reserve procedures.
Medtronic announced the final follow-up results from the CoreValve CE pivotal study, which demonstrated excellent long-term durability at four years in patients with severe aortic stenosis who were treated with the self-expanding CoreValve system. The results were presented for the first time at the 63rd Annual Scientific Session of the American College of Cardiology.
AccessClosure commercially launched its Mynx Ace vascular closure device, a safe and secure vascular closure product that provides consistent results with a new, easy-to-use deployment system to seal femoral artery access sites. The device joins the line of Mynx extravascular products that help care teams reduce time to haemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures. The commercial launch was announced as part of the annual meeting of the American College of Cardiology.
Medtronic announced the one-year results of the Melody transcatheter pulmonary valve US post-approval study, which found that real-world use of the Melody transcatheter pulmonary valve was associated with high procedural success, excellent valve function and few repeat procedures at the primary endpoint of six months. These results were sustained out to one year.
The Medicines Company reported a presentation of a pooled analysis of 5,800 patients in the EUROMAX and HORIZONS AMI trials, two international clinical trials comparing Angiomax (bivalirudin) versus heparin with or without glycoprotein IIb/IIIa inhibitors (GP IIb/IIIa) in patients with ST-segment elevation acute myocardial infarction (STEMI) undergoing percutaneous coronary intervention. EUROMAX and HORIZONS AMI studies were presented and published individually in September 2008 and October 2013, in The Lancet and The New England Journal of Medicine respectively.
OrbusNeich announced the completion of enrolment in the prospective, multicentre, all-comers REMEDEE registry (multicentre, prospective, clinical outcomes after deployment of the abluminal sirolimus coated bio-engineered stent post market registry) to evaluate the Combo stent for the treatment of coronary lesions in the setting of routine clinical care. The registry enrolled 1,000 patients at nine European high-volume percutaneous coronary intervention centres in France, Latvia, Luxembourg, The Netherlands, United Kingdom and Spain.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos